Teira, R, Diaz-Cuervo, H, Aragao, F, Munoz, J, Galindo, P, Merino, M, de la Fuente, B, Sepulveda, MA, Domingo, P, Garcia, J, Castano, M, Ribera, E, Geijo, P, Romero, A, Peraire, J, Deig, E, Roca, B, Martinez, E, Estrada, V, Montero, M, Berenguer, J, Espinosa, N. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort. HIV Research & Clinical Practice. 2021; 22(3)DOI:10.1080/25787489.2021.1955197. PMID:34410219. IF:1.676(Q4/9D).

Gonzalez-Cordon, A, Assoumou, L, Moyle, G, Waters, L, Johnson, M, Domingo, P, Fox, J, Stellbrink, HJ, Guaraldi, G, Masia, M, Gompels, M, De Wit, S, Florence, E, Esser, S, Raffi, F, Behrens, G, Pozniak, A, Gatell, JM, Martinez, E. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(9)DOI:10.1093/jac/dkab158. PMID:34120186. IF:5.758(Q1/2D).

Palacio-Vieira, J, Reyes-Uruena, JM, Imaz, A, Bruguera, A, Force, L, Llaveria, AO, Llibre, JM, Vilaro, I, Borras, FH, Falco, V, Riera, M, Domingo, P, de Lazzari, E, Miro, JM, Casabona, J, Gurgui M., Hernandez, J.. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC PUBLIC HEALTH. 2021; 21(1)DOI:10.1186/s12889-021-11613-y. PMID:34454444. IF:4.135(Q2/4D).

Rojas, J, de Lazzari, E, Negredo, E, Domingo, P, Tiraboschi, J, Ribera, E, Abdulghani, N, Puig, J, Mateo, MG, Podzamczer, D, Gutierrez, MM, Paredes, R, Clotet, B, Gatell, JM, Blanco, JL, Martinez, E, DOLAM Study Grp. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV. 2021; 8(8)DOI:10.1016/S2352-3018(21)00100-4. PMID:34358497. IF:16.070(Q1/1D).